UFlex subsidiary Asepto is set to start commercial operations at its $126 million Egypt facility by the end of 2026. This expansion doubles the firm's global capacity for aseptic liquid packaging. The move follows strong Q1 FY27 financial results, where the company saw significant profit growth and improved debt ratios.
UFlex Ltd is moving closer to commercial operations for its aseptic liquid packaging subsidiary, Asepto. The company's $126 million facility located in Ain Sokhna, Egypt, is expected to begin production before the end of 2026. This expansion is a significant milestone, as it aims to strengthen the company’s reach into European, Middle Eastern, and African markets.
The new plant has an installed annual capacity of 12 billion packs. This matches the capacity of the company's existing Sanand, Gujarat unit, effectively doubling its total production capacity to 24 billion packs. By setting up a hub in Egypt, the company intends to utilize the region's geographic advantages to reduce logistics timelines and serve international customers more efficiently.
This expansion comes at a time when UFlex has shown strong financial improvement. In the first quarter of the 2027 fiscal year, the company reported a consolidated net profit of ₹423.3 crore, which was a sharp increase compared to the same period in the previous year. Additionally, the company’s EBITDA margin stood at 17.0%. Management has also noted progress in financial health, with the debt-to-EBITDA multiple improving to 3.5x, down from 4.5x in the previous fiscal year. This indicates a focus on managing borrowing levels while funding major projects.
While the expansion highlights a growth phase, investors should consider the associated risks. Managing a large-scale facility in a foreign country introduces exposure to foreign exchange fluctuations, which can impact the profitability of overseas operations. There is also an execution risk involved in ramping up a new plant to full capacity. Furthermore, the company remains sensitive to commodity price volatility and geopolitical stability in the regions where it operates, both of which can influence profit margins.
Moving forward, the primary focus for investors will be the speed at which the Egypt plant reaches full production. The company has provided guidance for at least 35% growth in both top-line revenue and EBITDA for FY27. Consequently, the progress of this capacity utilization and the consistency of profit margins in the coming quarters will be the key factors for stakeholders to track.